Campto

Campto

irinotecan

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Concise Prescribing Info
Contents
Irinotecan HCl trihydrate
Indications/Uses
In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prior chemotherapy for advanced disease or as single agent in patients who have failed an established 5-FU containing treatment regimen.
Dosage/Direction for Use
Monotherapy 100-125 mg/m2 over 30-90 min IV infusion once wkly or 200-250 mg/m2 over 30-90 min IV infusion once every 2 wk, or 300-350 mg/m2 over 30-90 min IV infusion once every 3 wk. Combination therapy Starting dose: Irinotecan 125 mg/m2, bolus 5-FU 500 mg/m2 & folinic acid 20 mg/m2 for 6 wk or irinotecan 180 mg/m2, bolus 5-FU 400 mg/m2, 5-FU infusion 600 mg/m2 & folinic acid 200 mg/m2 for 6 wk.
Contraindications
Special Precautions
Hypersensitivity. Discontinue use if neutropenic fever or absolute neutrophil count <1,000/mm3 occurs. Cholinergic symptoms; hematology toxicities. Not to be used in patients w/ severe bone marrow failure. Patients w/ reduced UGT1A1 activity; late diarrhea; chronic inflammatory bowel disease &/or bowel obstruction; nausea & vomiting; gastric cancer. Symptomatic evidence of orthostatic hypotension in patients w/ dehydration. Preexisting lung disease, use of pneumotoxic drugs, radiation therapy & colony-stimulating factors. Extravasation; extensive prior irradiation; poor performance status. Avoid use w/ live vaccine. Hereditary fructose intolerance. May affect ability to drive & use machines. Hepatic insufficiency. Renal dysfunction. Not recommended for dialysis patients. Women of childbearing potential. Pregnancy. Not to be used during lactation. Childn. Elderly ≥65 yr.
Adverse Reactions
Late &/or early diarrhea, nausea, vomiting, abdominal cramping/pain, anorexia, stomatitis; leukopenia, anemia, neutropenia; asthenia, fever; decreased wt, dehydration; alopecia; thromboembolic events.
Drug Interactions
Increased systemic exposure w/ CYP3A4 &/or UGT1A1 inhibitors. Increased exposure to SN-38 w/ ketoconazole & atazanavir sulfate. Reduced exposure to SN-38 w/ CYP3A-inducing anticonvulsant drugs eg, carbamazepine, phenobarb or phenytoin & St. John's wort. Prolonged neuromuscular blocking effects. Exacerbated adverse effects w/ antineoplastic agents. Enhanced lymphocytopenia w/ dexamethasone. Worsened diarrhea incidence or severity w/ laxatives. Dehydration w/ diuretics.
ATC Classification
L01CE02 - irinotecan ; Belongs to the class of Topoisomerase 1 (TOP1) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Campto infusion 100 mg/5 mL
Packing/Price
1's
Form
Campto infusion 40 mg/2 mL
Packing/Price
1's
Form
Campto infusion 300 mg/15 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in